DPI: A paradigm shift from nebulizers to dry powder inhalers

Simple item page
dc.contributor.authorPatil, PSen_US
dc.contributor.authorMahajan, HS.en_US
dc.date.accessioned2025-05-09T10:45:50Z
dc.date.available2025-05-09T10:45:50Z
dc.date.issued2024-10
dc.description.abstractDrug delivery to pulmonary routes was once considered a challenging task. The emergence of inhalation therapy paved the way for drug delivery to the lungs. With various advances in inhalation therapy, modern-age drug delivery systems include nebulizers, pressurized metereddose inhalers, and dry powder inhalers (DPIs). The following review discusses the development stages of DPIs and also gives an insight into the current formulation aspects of DPI, animal models used for evaluation of drug release parameters, and the Anderson cascade impactor and its possible correlation with human respiratory tract with regards to drug deposition and particle size. Today, DPIs have brought about a revolution in drug delivery to lungs, and also offer more advantages with regards to consistency of dose delivered, stability, and ease of administration. Dry powders have been extensively used in the treatment of asthma and various other respiratory disorders. With the introduction of nanoformulations, a wide sector of researchers is working toward developing DPIs that may be used to target diseases like lung cancer.en_US
dc.identifier.affiliationsDepartment of Pharmaceutics, R.C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Maharashtra, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmaceutics, R.C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Maharashtra, Indiaen_US
dc.identifier.citationPatil PS, Mahajan HS.. DPI: A paradigm shift from nebulizers to dry powder inhalers. Annals of the National Academy of Medical Sciences (India). 2024 Oct; 60(4): 250-260en_US
dc.identifier.issn0379-038X
dc.identifier.issn2454-5635
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/245750
dc.languageenen_US
dc.publisherNational Academy of Medical Sciencesen_US
dc.relation.issuenumber4en_US
dc.relation.volume60en_US
dc.source.urihttps://dx.doi.org/10.25259/ANAMS_45_2024en_US
dc.subjectAerodynamic diameteren_US
dc.subjectdry powder inhalersen_US
dc.subjectpreclinical testingen_US
dc.subjectlactoseen_US
dc.subjectnanoformulationsen_US
dc.titleDPI: A paradigm shift from nebulizers to dry powder inhalersen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
anams2024v60n4p250.pdf
Size:
774.28 KB
Format:
Adobe Portable Document Format
Download
Collections
Annals of the National Academy of Medical Sciences (India)